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Abstract
Advances in breast cancer treatment have improved disease-free survival and overall survival in women with
early-stage breast cancer. However, these improvements may be attenuated by the adverse cardiovascular effects
associated with breast cancer adjuvant therapy. Exercise may be a potential strategy to counteract these toxicities.
The purpose of this paper is to provide an overview on the adverse cardiovascular effects of breast cancer therapy
as well as the evidence supporting the potential cardioprotective effects of exercise training in breast cancer
patients during and after treatment. We will also discuss research gaps and avenues for future research.
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Background
Breast cancer is the most common malignancy in
women in the United States, with an estimated 231,840
new cases expected to be diagnosed in 2015 [1]. However,
earlier detection and advances in adjuvant therapy have
resulted in steadily decreasing rates of breast cancer-
related death [2]. The 5-year survival rate for breast cancer
has improved from 74.6 % in women diagnosed from
1975–1979 to 89.4 % in 2005–2011 [3]. In the U.S. today,
there are an estimated 2.8 million survivors of breast
cancer, representing 22 % of all cancer survivors [4]. As
such, breast cancer patients are living longer and thus are
increasingly at risk for the late-occurring adverse effects of
cancer therapy. Most notably, breast cancer survivors are
at increased risk for cardiovascular disease (CVD) as
defined by events such as heart failure and coronary artery
disease (CAD). In fact, CVD has now surpassed breast
cancer as the leading cause of death among survivors of
early-stage breast cancer after 65 years of age [5, 6]. As
such, prevention and management of adverse cardiovascu-
lar effects is becoming an increasingly important clinical
issue in early-stage breast cancer. Current strategies have
focused on screening and prevention of cardiomyopathy
and include treatment modification based on patient-
specific risk profiles, intensive monitoring for early
detection of cardiovascular injury using imaging and
circulating biomarkers, and pharmacologic intervention
with cardioprotective medications (e.g. beta-blockers or
ACE-inhibitors) [7].
Exercise, defined as a regular regimen of structured
physical activity performed with the goal of improving
health or physical fitness [8] is increasingly being recog-
nized as an effective strategy to counter the adverse
effects of cancer therapy. The cardiovascular benefit of
exercise in the non-cancer setting has been extensively
studied, with regular moderate to vigorous-intensity
exercise currently recommended by the American Heart
Association to reduce cardiovascular risk including low-
ering of cholesterol and blood pressure [9]. The purpose
of this paper is to review the adverse cardiovascular
effects associated with breast cancer therapy as well as
the available evidence on the efficacy of exercise to
mitigate adverse cardiovascular effects in breast cancer
patients during and after treatment. We will also discuss
gaps in knowledge and avenues for future research.
Adverse cardiovascular effects associated with breast
cancer therapy
Treatment for breast cancer varies depending on multiple
tumor-specific factors including size, lymph node involve-
ment, presence or absence of distant metastasis, hormone
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into consideration these factors, treatment generally
utilizes a multimodality approach of surgery, systemic
therapy (e.g. chemotherapy, targeted therapy, or endocrine
therapy), and radiotherapy. Patient-specific factors and
other comorbidities are then taken into consideration in
determining the optimal treatment regimen. Here we will
review the adverse cardiovascular effects associated with
breast cancer therapy.
Cardiomyopathy and heart failure
Anthracyclines are a key component of treatment
regimens for breast cancer. However, their use is limited
by cumulative and dose-dependent cardiotoxicity, which
was first reported in the 1970s [11]. Cardiomyopathy
and heart failure are the most common clinical manifest-
ation of anthracycline cardiotoxicity. In a review of 4,018
patients treated with doxorubicin, the incidence of
doxorubicin-induced heart failure was 2.2 %, and the risk
of heart failure increased substantially at cumulative
doses of > 400 mg/m2 [11]. In a retrospective analysis of
630 patients randomized to doxorubicin plus placebo in
three phase III studies by Swain, et al., the percentage of
patients with doxorubicin-induced heart failure was 5 at
a cumulative dose of 400 mg/m2, 26 at a dose of
550 mg/m2, and 48 % at a dose of 700 mg/m2 [12].
Anthracycline cardiotoxicity can occur acutely within
weeks of initial anthracycline exposure, but more
commonly presents months to years after treatment.
The underlying mechanism of anthracycline-induced
myocardial damage has been attributed to multiple
adverse effects on cardiomyocytes including oxidative
damage from an increase in reactive oxygen species
(ROS) formation, alterations in iron homeostasis, and
mitochondrial dysfunction [13–15]. These ultimately
result in irreversible cardiomyocyte death, and has been
classified as type I cancer therapy related cardiac
dysfunction (CTRCD) [16]. More recent studies suggest
that topoisomerase 2β inhibition may be a key mediator
of anthracycline cardiotoxicity [17].
The risk for cardiomyopathy or heart failure is further
compounded in patients with HER2-positive disease who
receive anthracycline chemotherapy plus anti-HER2 ther-
apy (e.g. trastuzumab). The mechanism of trastuzumab-
induced cardiotoxicity is thought to be related to blockade
of HER2 signaling that is critical for normal cellular
growth and repair mechanisms in cardiomyocytes [18]. In
early trials of trastuzumab for metastatic breast cancer,
cardiotoxicity was observed in 27 % of patients treated
with concurrent anthracycline and trastuzumab therapy,
of which 16 % had NYHA class III or IV heart failure [19].
The risk of cardiotoxicity decreased in subsequent adju-
vant trials of trastuzumab after several safeguards were
implemented, including sequential dosing of trastuzumabfollowing anthracycline-based therapy. In these adjuvant
trials the observed rate of heart failure and asymptomatic
decline in left ventricular ejection fraction was 0.4–4.1
and 7.1 % - 18.6 %, respectively [20–22].
Coronary artery disease
Radiotherapy reduces the risk of recurrence and death
from breast cancer, but increases the risk of CAD due to
incidental radiation exposure to cardiac structures
[23, 24]. Other less common adverse effects associated
with radiotherapy include pericardial disease, valvular
dysfunction, and conduction abnormalities [25]. In a
meta-analysis conducted by the Early Breast Cancer Trial-
ists’ Collaborative Group (EBCTCG) of 40 randomized
controlled trials involving 19,582 women, breast cancer
mortality was reduced (38.4 % vs. 42.1 %, p-0.0001) but
vascular-related mortality was increased (death rate ratio
1.30, p = 0.0007) with radiotherapy [26]. Awareness of
adverse cardiovascular effects from older radiotherapy
regimens from the 1960s and 1970s led to modifications
in technique in order to minimize cardiac radiation expos-
ure. In a study by Hooning, et al., the hazard ratio for
CVD decreased from 1.49 (95 % CI 1.124 to 1.94) in
patients irradiated between 1970–1979 to 1.35 (95 % CI
0.90 to 2.02) in patients irradiated with more modern
regimens between 1980–1986 [27].
The extent to which improvements in radiotherapy
techniques can reduce harms to the cardiovascular
system through dose reduction remains an important
clinical question. In a population based case–control
study of 2,168 women in Sweden and Denmark with
breast cancer treated with radiotherapy between 1958
and 2001, Darby, et al. studied the association between
risk of a major coronary event (i.e. myocardial infarction,
coronary revascularization, or death from ischemic heart
disease) and radiation dose to the heart. The rate of
major coronary events increased by 7.4 % for each
additional 1Gy of radiation to the heart, and an increase
in cardiac risk was present even at low radiation doses ≤
4 Gy [28]. Of note, results of this study are reflective of
older radiation techniques prior to the introduction of
newer strategies that further minimize radiation ex-
posure to the heart (e.g. computed tomographic plan-
ning or breath-hold technique). Nonetheless, evidence
of residual cardiac risk despite a low mean radiation
dose to the heart may provide the rationale for newer
techniques such as proton beam therapy that can
further reduce radiation exposure to cardiac struc-
tures, however this requires further investigation.
Effects secondary to adjuvant therapy: weight gain and
physical inactivity
Beyond the direct insults of systemic therapy and
radiotherapy, breast cancer patients are also subject
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physical inactivity, both of which have been associated
with adverse cardiovascular events in the non-cancer
population [29, 30]. The occurrence of weight gain is
common during the first year after breast cancer diagno-
sis. In a study by Goodwin, et al. of 535 women with newly
diagnosed breast cancer, 84 % of patients gained weight
after 1 year with a mean weight gain of 1.6 kg [31]. Treat-
ment with chemotherapy was an independent predictor of
weight gain, with mean weight increase of 2.5 kg among
patients receiving chemotherapy. Physical activity has also
been shown to decrease significantly after breast cancer
diagnosis. In the Health, Eating, Activity, and Lifestyle
(HEAL) study by Irwin, et al., physical activity levels
decreased by an estimated 2 h per week in women with
breast cancer within 1 year of diagnosis compared to
baseline [32]. The largest decrease in physical activity was
observed in women treated with radiation and chemother-
apy. By 3 years after diagnosis, only 32 % of breast cancer
survivors were meeting the recommended levels of phys-
ical activity (i.e. 150 min/week of moderate- to vigorous-
intensity activity) [33].
Cardiorespiratory impairment
Assessment of early and late cardiovascular effects in
breast cancer survivors has primarily focused on the
evaluation of left ventricular (LV) systolic function.
However, breast cancer therapy causes varying degrees
of direct (e.g. cardiac dysfunction, pulmonary dysfunc-
tion, endothelial dysfunction, skeletal muscle dysfunc-
tion) and indirect (e.g. decreased lean body mass,
deconditioning) perturbations to the global cardiovas-
cular system that extend beyond the heart. This has
been described as the “multiple-hit hypothesis” in
which multiple sequential exposures to cardiotoxic
treatment are coupled with indirect lifestyle changes
and result in overt CVD among breast cancer survi-
vors [10]. Cardiopulmonary exercise testing (CPET)
provides an evaluation of exercise capacity (or
VO2peak), which reflects the ability of the cardiovascu-
lar system to deliver oxygen to exercising skeletal
muscle and capacity of skeletal muscle to utilize oxy-
gen [34]. Tools such as CPET provide optimal
characterization of global cardiovascular impairment
related to cancer treatment.
Impaired exercise capacity is becoming a central defin-
ing feature in breast cancer patients. In two cross-
sectional studies, exercise capacity was significantly
lower in breast cancer survivors evaluated several years
after completion of therapy compared to age-matched
healthy controls [35, 36]. Subsequently, we performed a
cross-sectional study in 248 women to evaluate cardio-
pulmonary function across the breast cancer continuum
– before, during, and after adjuvant therapy fornonmetastatic disease, as well as during therapy in the
metastatic setting [37]. Despite normal resting left ven-
tricular ejection fraction, women with breast cancer had
significant impairments in exercise capacity with mean
VO2peak that was 17.8 mL/kg/min or 27 % below age-
matched healthy sedentary women. Furthermore, in
women with metastatic disease the hazard ratio for
death with a VO2peak of > 1.09 L/min was 0.32 (95 % CI,
0.16 to 0.67, p = 0.002) compared with a VO2peak ≤
1.09 L/min, suggesting that VO2peak has prognostic sig-
nificance. The Alberta moving beyond breast cancer
(AMBER) study is an ongoing prospective cohort study
that will quantitatively measure physical activity and ex-
ercise capacity in 1,500 survivors of early breast cancer
[38]. The primary goal of this study is to identify associa-
tions between physical activity and exercise capacity on
disease outcomes (e.g. breast cancer recurrence and
overall survival).
Cardiovascular benefits of exercise in breast cancer
In adults without cancer, exercise has been associated
with many cardiovascular health benefits including
reduced risk of ischemic heart disease, stroke, hyperten-
sion, dyslipidemia, diabetes, and metabolic syndrome
[39–45]. The known cardioprotective effect of exercise
has provided a strong rationale to investigate the poten-
tial cardiovascular benefit of exercise in the context of
breast cancer therapy. Over the last two decades, there
has been increasing research interest in the role of
exercise to mitigate early and late adverse effects of
cancer therapy in breast cancer survivors. Importantly,
current evidence has demonstrated the safety and feasi-
bility of exercise during and after cancer treatment. In a
meta-analysis of 82 studies on physical activity interven-
tions in cancer survivors (83 % of studies were among
women with early breast cancer), Speck, et al. reported
that exercise was generally well tolerated and safe with
few reported adverse events during or after cancer treat-
ment [46]. In the following sections we will review data
from epidemiologic, preclinical, and clinical studies on
the cardiovascular benefits of exercise in breast cancer.
Epidemiologic studies
Physical activity and weight gain are known predictors
of cardiovascular outcomes in non-cancer populations
[10]. Furthermore, observational studies have shown that
physical activity is associated with reductions in all-
cause mortality in women with early-stage breast cancer
[47, 48]. However, the prognostic value of physical activ-
ity on cardiovascular events in breast cancer survivors
has not been well studied. Accordingly, we investigated
the association between physical activity and CVD
outcomes among 2,973 women with breast cancer in
two population-based cohort studies, the Life After
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[Jones LW, et al.: Exercise and risk of cardiovascular
events in women with non-metastatic breast cancer, sub-
mitted]. In this analysis, increasing levels of physical ac-
tivity were associated with a reduction in cardiovascular
events (e.g. coronary artery disease or heart failure) and
all-cause mortality. Compared to women engaged in less
than 2 MET-hrs/week of leisure-time physical activity,
there was a 9 % (HR 0.91, 95 % CI 0.76 to 1.09), 21 %
(HR 0.79, 95 % CI 0.66 to 0.96), and 35 % (HR 0.65,
95 % CI 0.53 to 0.80) reduction in the risk of cardiovas-
cular events for women engaged in 2 to 10.9 MET-hrs/Table 1 Summary of studies investigating the cardiovascular effects
Author Patient population Exercise
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50 % - 6
3 d/wkweek, 11 to 24.5 MET-hours/week, and ≥ 24.5 MET-hrs/
week, respectively.
Preclinical studies
Animal models investigating the effect of exercise training
on cardiovascular toxicity related to breast cancer therapy
have largely focused on a model of anthracycline-induced
model of cardiomyopathy. Dolinsky, et al. reported that
doxorubicin-induced LV remodeling was attenuated by
exercise training (i.e. treadmill running) in mice [49].
Similarly, Lien, et al. showed that exercise training prior to
doxorubicin treatment attenuated cardiac dysfunction in aof exercise interventions during breast cancer treatment
intervention Outcome
ed aerobic exercise, 15–45
t 60 % - 80 % of VO2peak, 3 d/wk
supervised resistance exercise, 2
exercises at 60 % - 70 % of
tion maximum, 3 d/wk (n = 82);
care (n = 82). All interventions
ed for the duration of
herapy (mean 17 wks).
↑ VO2peak and ↑ self-esteem with
aerobic exercise compared to usual
care; ↑ self–esteem, ↑ muscular
strength, and ↑ lean body mass with
resistance training compared to
usual care.
ed aerobic exercise, 25–30
t 55 % - 75 % of VO2peak, 3 d/wk
96); supervised aerobic exercise
- 75 % of VO2peak, 50–60 min/d,
(HIGH, n = 101); or combined
ed aerobic exercise (25–30
nd resistance exercise (2 sets
rcises at 60 % - 75 % of
tion maximum), 50–60 min/d, 3
OMB, n = 104). All interventions
ed for the duration of
herapy (mean 16 weeks).
Decline in VO2peak attenuated with
HIGH compared to COMB. No
significant difference between HIGH
and STD on VO2peak.
ed aerobic exercise, 30–60
t 60 % - 90 % of VO2peak,
× 4 mo.
No change in VO2peak, SBP, or DBP;
↑ LVEDV, ↑LVESV, and ↓ LVEF with
exercise.
ed aerobic exercise, 15–45
t 60 % - 70 % of VO2peak and
interval sessions, 3 d/wk × 12
10); or usual care (n = 10)
↑ VO2peak with exercise
ed aerobic exercise, 30 min at
0 % of VO2peak, 3 d/wk × 8 wks
or control (n = 19)
↓ HR, ↓ SBP, ↑ VO2peak with aerobic
exercise compared to control.
ed aerobic exercise at 60 % -
maximum heart rate, 3 d/wk ×
(n = 18); non-aerobic stretching
ibility exercises (n = 11); or
(n = 16)
↑ VO2peak with aerobic exercise
compared to non-aerobic
stretching and control.
cted exercise at 50 % - 60 % of
5 d/wk × 26 wks (n = 40);
ed exercise at 50 % to 60 %% of
3 d/wk and self-directed exercise
level 2 d/wk × 26 wks (n = 42);
care (n = 41).
↑ VO2peak in supervised exercise
group compared to control in
patients not receiving
chemotherapy; no difference
between groups in VO2peak among
patients receiving chemotherapy.
ased walking program at
0 % of maximum heart rate,
× 12 wks.
↑ VO2peak and ↑ 6MWT distance.
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both studies reported that exercise training prevented a
decline in expression of sarcoplasmic/endoplasmic
reticulum calcium-ATPase (SERCA) 2a, which has been
implicated in the pathogenesis of other cardiomyopathies
(e.g. ischemic or dilated cardiomyopathy) [51]. Other
reported benefits of exercise training in animal models of
anthracycline cardiotoxicity include maintenance of
normal cardiac mitochondrial function [52], improvement
in measures of LV function (e.g. dP/dtmax and dP/dtmin)
[53–55], increased expression of glutathione and heat
shock protein 72, and decreased expression of p53
[56, 57]. Findings from these preclinical studies sug-
gest that exercise may be an effective strategy to pre-
vent adverse cardiovascular effects of breast cancer
therapy and provide a rationale for clinical studies of
exercise during and after breast cancer treatment.
Clinical studies – during treatment
Several studies have evaluated the effects of exercise
during breast cancer therapy for the prevention of ad-
verse CV effects (Table 1). Courneya, et al. randomized
242 patients initiating adjuvant chemotherapy to three
groups – usual care, supervised resistance exercise, or
supervised aerobic exercise [58]. After a mean duration
of 17 ± 4 weeks of exercise training, there was no signifi-
cant change in patient-reported outcomes of quality ofTable 2 Summary of studies investigating the cardiovascular effects of
Author Patient population
Courneya et al. 2003 [62] 53 post-menopausal breast cancer
survivors after completion of surgery,
radiotherapy, and/or chemotherapy
Daley et al. 2006 [73] 108 women treated for breast cancer
12 to 36 months previously
Hutnick et al. 2005 [74] 49 survivors of stage I-III breast
cancer
Pinto et al. 2005 [75] 86 women after completing
treatment for stage 0-II
breast cancer
Schneider et al. 2007 [63] 113 women with breast cancer:
96 completed radiation and/or
chemotherapy, and 17 undergoing
concurrent cancer treatment
with exerciselife, fatigue, depression, or anxiety. However, aerobic
exercise was able to prevent a decline in VO2peak
(25.2 mL/kg/min at baseline to 25.7 mL/kg/min at
follow-up) that was observed in the usual care group
(24.8 mL/kg/min at baseline to 23.5 mL/kg/min at
follow-up). In a follow-up trial, and also the largest
randomized controlled trial to date of exercise training
during therapy, Courneya, et al. randomized 301 patients
to three exercise regimens: standard (25–30 min of
aerobic exercise), high (5–60 min of aerobic exercise), or
combined high plus resistance exercise. All exercise
groups experienced a decline in VO2peak from baseline
to completion of chemotherapy, however this decline
was partially attenuated in the high exercise group
(ΔVO2peak -2.5 mL/kg/min) versus standard or combined
groups (ΔVO2peak -3.4 mL/kg/min and −3.6 mL/kg/min,
respectively) [59]. Studies to investigate the effect of exer-
cise training during breast cancer treatment on cardiac
structure or function are limited. In the only study by
Haykowsky, et al., aerobic training did not prevent
trastuzumab-induced LV remodeling or decline in left
ventricular ejection fraction after 4 months of treatment
among women with HER2-positive breast cancer [60].
Clinical studies – after treatment
Exercise has been increasingly recognized for its import-
ance in the rehabilitation of patients after cancer therapyexercise interventions after completion of breast cancer treatment
Exercise intervention Outcome
Supervised aerobic exercise,
15 – 35 min/d at 70 % - 75 %
of VO2peak, 3 d/wk × 15 wks
(n = 25); or control (n = 28).
↑ VO2peak and ↑ self-reported QOL
with aerobic exercise compared to
control.
Supervised aerobic exercise,
50 min/d at 65 % - 85 %
maximum heart rate and RPE
12–13, 3 d/wk × 8 wks (n =34);
exercise-placebo, 50 min/d of
light-intensity body conditioning/
stretching, 3 d/wk × 8 wks
(n = 36); or usual care (n = 38).
↑ fitness measured by submaximal
walking test with aerobic exercise
and exercise-placebo compared to
usual care.
Supervised aerobic exercise,
10 – 20 min/d at 60 % - 75 % of
VO2peak, plus resistance training,
total session 40–90 min/d, 3
d/wk × 6 months (n = 28); or
control (n = 21).
↑ VO2peak and ↑ upper body
strength
Home-based aerobic exercise,
10 – 30 min/d at 55 % - 65 % of
maximum heart rate, 5 d/wk ×
12 wks (n = 43); or control
(n = 43)
↑ fitness (↓ time for 1-mile walk
test); no change in BMI or % body
fat with aerobic exercise compared
to control.
Supervised aerobic exercise,
60 min/d at 40 %–75 % of
heart rate reserve, 2–3 d/wk ×
6 months
↑ VO2peak, ↓ SBP, ↓ resting heart
rate, ↓ fatigue with aerobic
exercise after completion of
cancer treatment.
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et al. was performed to determine the effects of exercise
training on cardiopulmonary function and quality of life
in breast cancer survivors after completion of therapy (e.g.
surgery, radiotherapy, and/or chemotherapy) [62]. In this
study of 53 patients a median of 14 months after therapy,
exercise training consisted of 3 weekly supervised sessions
for 15 weeks. VO2peak increased by 0.24 L/min in the
exercise group, whereas it decreased by 0.05 L/min in the
control group. A similar study by Schneider, et al. included
113 women with a history of breast cancer and evaluated
the effect of 2–3 weekly sessions of supervised exercise
training for 6 months. Exercise training was associated
with improvement in several parameters of cardiopulmo-
nary function including systolic blood pressure, heart rate,
and VO2peak [63]. Other beneficial effects of exercise after
treatment include improved upper and lower body
strength, body weight, body fat percentage, and overall
quality of life [46]. No data are available on the effect of
exercise training in cancer survivors to mitigate treatment-
induced changes in cardiac structure and function.
Suggested approach to exercise
Based on the growing evidence on the safety and efficacy
of exercise training during and after cancer therapy, theFig. 1 Suggested algorithm for exercise prescriptions in breast cancer patie
patients seeking to begin a regular exercise regimen, taking into consideratio
details. Additional consultation should be considered at the discretion of the
Sports Medicine (ACSM) guidelines should follow an incremental and step-wi
perform 20–60 min of moderate to vigorous intensity activity at least 5 days p
levels are achieved. Adapted from references [66, 67], with permissionAmerican College of Sports Medicine (ACSM) convened
an expert panel to formulate exercise guidelines for
cancer survivors [64]. These guidelines are consistent
with the Physical Activity Guidelines published by the
US Department of Health and Human Services [65] and
recommend 150 min of moderate-intensity exercise or
75 min of vigorous-intensity exercise per week. For pa-
tients diagnosed with cancer, it should be acknowledged
that reaching this level of exercise is a long-term goal
that will likely require progressive and step-wise
increments in frequency, intensity, time, and type of
exercise. Furthermore, exercise prescriptions must be
individualized on the basis of baseline health status, co-
morbid conditions, treatment plan, and overall prognosis
[66]. A suggested approach to exercise for breast cancer
patients (during and after cancer treatment) is outlined
in Fig. 1.
Gaps in knowledge and future directions
Despite the important body of research published to
date on the efficacy of exercise training during and after
breast cancer treatment, many questions remain un-
answered. Overall, data from clinical studies suggest that
exercise may attenuate treatment related decline in
VO2peak during breast cancer treatment and improvents. A pre-exercise screening assessment should be considered for
n baseline exercise level, comorbid conditions, and cancer management
treating provider. Patients who do not meet the American College of
se approach to increasing exercise levels. The long-term goal is to
er week. Resistance training can be considered once target exercise
Yu and Jones Cardio-Oncology  (2016) 2:1 Page 7 of 9VO2peak after breast cancer treatment. Other benefits are
also observed in patient reported outcomes such as
quality of life and fatigue. However, the prognostic sig-
nificance of this improvement remains unknown. Given
the increased risk for CVD in breast cancer survivors,
the question of whether exercise can improve cardiovas-
cular outcomes is of particular importance. Additional
epidemiologic studies utilizing patient cohorts with well
characterized data on exercise or physical activity expos-
ure and cardiovascular outcomes are needed to further
define the cardiovascular benefit of exercise in breast
cancer patients. Due to the latency period between
breast cancer treatment and cardiovascular outcomes,
prospective studies to answer this question are challen-
ging and will require long-term follow-up. In the ab-
sence of this data, studies investigating exercise-induced
changes on surrogate measures of cardiovascular struc-
ture or function (e.g. imaging or circulating biomarkers)
may provide further insight into the cardiovascular
benefit of exercise. Other important areas of future
research include identifying patient factors that predict
response to exercise, and investigating the optimal inten-
sity, timing, and duration of exercise. Finally, the poten-
tial for exercise to improve breast cancer outcomes is an
exciting new area of research that warrants further
investigation.
Conclusion
Breast cancer treatment has led to significant survival
gains but has been associated with adverse cardiovascular
effects. Current evidence suggests that exercise may be an
effective strategy to mitigate treatment-associated cardio-
vascular effects in breast cancer patients such as decreased
VO2peak. Additional studies are needed to further define
the effect of exercise on cardiovascular and cancer
outcomes.
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